HUP0201729A3 - Inhibitors of the integrin alpha v betha 6 - Google Patents

Inhibitors of the integrin alpha v betha 6

Info

Publication number
HUP0201729A3
HUP0201729A3 HU0201729A HUP0201729A HUP0201729A3 HU P0201729 A3 HUP0201729 A3 HU P0201729A3 HU 0201729 A HU0201729 A HU 0201729A HU P0201729 A HUP0201729 A HU P0201729A HU P0201729 A3 HUP0201729 A3 HU P0201729A3
Authority
HU
Hungary
Prior art keywords
betha
inhibitors
integrin alpha
integrin
alpha
Prior art date
Application number
HU0201729A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HUP0201729A2 publication Critical patent/HUP0201729A2/hu
Publication of HUP0201729A3 publication Critical patent/HUP0201729A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HU0201729A 1999-06-26 2000-06-13 Inhibitors of the integrin alpha v betha 6 HUP0201729A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19929410A DE19929410A1 (de) 1999-06-26 1999-06-26 Inhibitoren des Integrins avß6

Publications (2)

Publication Number Publication Date
HUP0201729A2 HUP0201729A2 (en) 2002-08-28
HUP0201729A3 true HUP0201729A3 (en) 2005-01-28

Family

ID=7912712

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201729A HUP0201729A3 (en) 1999-06-26 2000-06-13 Inhibitors of the integrin alpha v betha 6

Country Status (17)

Country Link
EP (1) EP1189930A1 (hu)
JP (1) JP2003503422A (hu)
KR (1) KR20020015704A (hu)
CN (1) CN1358195A (hu)
AR (1) AR024472A1 (hu)
AU (1) AU771099B2 (hu)
BR (1) BR0011954A (hu)
CA (1) CA2377224A1 (hu)
CZ (1) CZ20014484A3 (hu)
DE (1) DE19929410A1 (hu)
HU (1) HUP0201729A3 (hu)
MX (1) MXPA01013247A (hu)
NO (1) NO20016341L (hu)
PL (1) PL352374A1 (hu)
SK (1) SK18722001A3 (hu)
WO (1) WO2001000660A1 (hu)
ZA (1) ZA200200673B (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
ATE394415T1 (de) * 2003-02-06 2008-05-15 Merck Patent Gmbh Peptidische sulfonamide
GB0520068D0 (en) * 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
BRPI0715141A2 (pt) 2006-08-03 2013-06-04 Astrazeneca Ab agente de ligaÇço alvejante, anticorpo isolado, fragmento de anticorpo isolado, molÉcula de Ácido nucleico, vetor, cÉlula hospedeira, mÉtodos para produzir um agente de ligaÇço alvejado, para produzir um anticorpo, para produzir um fragmento de anticorpo, para tratar um tumor maligno em um animal, para tratar inflamaÇço, e para inibir a interaÇço de alfabeta6 com seu ligando, e, conjugado
IL266343B2 (en) * 2016-11-01 2024-01-01 Arrowhead Pharmaceuticals Inc Ligands of alpha-V beta-6 integrin and their uses
BR112020006901A2 (pt) 2017-11-01 2020-10-13 Arrowhead Pharmaceuticals, Inc. ligantes de integrina e usos dos mesmos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06511477A (ja) * 1991-05-14 1994-12-22 ボード　オブ　リージェンツ　オブ　ザ　ユニバーシティ　オブ　オクラホマ 炎症のペプチド阻害剤
ATE286742T1 (de) * 1997-08-08 2005-01-15 Univ California Behandlung von nierenfibrose durch antikörper gegen integrin alpha-v-beta 6
CN1335853A (zh) * 1998-12-19 2002-02-13 默克专利股份公司 整联蛋白αvβb的抑制剂

Also Published As

Publication number Publication date
DE19929410A1 (de) 2000-12-28
SK18722001A3 (sk) 2002-05-09
BR0011954A (pt) 2002-05-07
EP1189930A1 (de) 2002-03-27
HUP0201729A2 (en) 2002-08-28
WO2001000660A1 (de) 2001-01-04
CN1358195A (zh) 2002-07-10
NO20016341D0 (no) 2001-12-21
AU771099B2 (en) 2004-03-11
NO20016341L (no) 2002-02-25
ZA200200673B (en) 2003-04-24
AU6263000A (en) 2001-01-31
AR024472A1 (es) 2002-10-02
JP2003503422A (ja) 2003-01-28
MXPA01013247A (es) 2002-07-02
CZ20014484A3 (cs) 2002-04-17
CA2377224A1 (en) 2001-01-04
KR20020015704A (ko) 2002-02-28
PL352374A1 (en) 2003-08-25

Similar Documents

Publication Publication Date Title
IL149374A0 (en) New use and novel n-azabicyclo-amide derivatives
HRP20060251B1 (hr) Supstituirani oksazolidinoni i njihova uporaba
HK1040076A1 (zh) 作為整聯蛋白抑制劑的喹嗪酮
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
HK1053657A1 (en) Novel heterocyclic compounds and salts thereof andmedicinal use of the same
IL139899A (en) Uracil compounds and use thereof
AU2001276027A1 (en) Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors
GB0023323D0 (en) Arylhydantoin derivatives and uses thereof
HK1048318B (zh) 取代的3-苯基-5-烷氧基-1，3，4-噁二唑-2-酮及其作為脂酶抑制劑的用途
AU4678400A (en) Laminin 8 and methods for its use
EP1153022A4 (en) PROTEASE INHIBITORS
HUP0201729A2 (en) Inhibitors of the integrin alpha v betha 6
HK1049667A1 (zh) 整聯蛋白αVβ3的抑制劑
EP1218407A4 (en) USES OF KAPPA-CONOTOXIN PVIIA
EP1229913A4 (en) SUBSTITUTED 1-BENZAZEPINE AND THEIR DERIVATIVES
HK1049666A1 (zh) 新型整合蛋白αVβ3抑制劑
PL350963A1 (en) Use of arylalkanoylpyridazines
IL147103A0 (en) Substituted isoquinoline derivatives and their use as anticonvulsants
PL365729A1 (en) Gem-substituted alpha v beta 3 integrin antagonists
HK1055288A1 (en) Novel aqueous composition and use of the same
PL354184A1 (en) The prv-1 gene and use thereof
GB9929581D0 (en) Comjpositions and their use
SI1214302T1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
GB0028459D0 (en) Glor 2
GB9923117D0 (en) Insect-paper and methods for its formation and use